Innovation comes at a price, one that health insurers may hesitate to pay. While some patients reap a benefit from breakthrough drugs, others do not.
Opting for cheaper prescription drugs seems like an obvious way to cut health care costs. The assumption has led health plans to employ utilization management
WASHINGTON – Today, the Alliance for Patient Access made the following statement regarding the Institute for Clinical and Economic Review’s (ICER) final report on the value of
By Stuart Isaacson, MD Most all of us know someone living in a long-term care facility – a friend, a former neighbor, a family member.
Nearly one in five Americans with hepatitis C spends time behind bars each year, making the prison system an opportune environment to test and cure
Accessing innovative cardiovascular drugs may soon get harder. A new publication from the Institute for Clinical and Economic Review, a drug price analysis group, assigns
Physician organization urges the Senate to reauthorize the bill before leaving for August recess WASHINGTON – The Alliance for Patient Access (AfPA) made the following statement